Observational studyJournal for immunotherapy of cancer2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLC.
Observational study in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor draining lymph nodes in non-small cell lung cancer:Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-draining lymph nodes (TDLN) play a key role in inducing and promoting antitumor immunity. TDLN are commonly situated near the primary tumor and are therefore often exposed to therapeutic radiation. The impact of induction therapies comprising concurrent immunotherapy and radiation on TDLN is poorly understood. We studied the immune-modulating effects in TDLN of patients with T3-4N0-2 non-small cell lung cancer (NSCLC) using a combination of spatial transcriptomics and immunohistochemical analyses.
methodsThis observational cohort study collected TDLN from 2 groups: (1) patients from the INCREASE trial who were treated with neoadjuvant ipilimumab/nivolumab (IPI/NIVO) plus chemoradiotherapy (CRT) (n=25) and (2) a matched control cohort of patients with NSCLC who had neoadjuvant CRT only (n=25). TDLN were classified based on the cumulative dose of radiation received, categorized as low (≤5 Gy), intermediate (20-30 Gy), or high dose (50-60 Gy). The TDLN were subjected to duplex immunohistochemistry of CD8/Ki67, PD-1/FOXP3, and CD8/cleaved caspase-3. On a subset of TDLN, additional GeoMx spatial transcriptomics profiling of CD8/Ki67+T cell hotspots was carried out.
resultsAfter addition of IPI/NIVO to CRT in the INCREASE cohort, resected TDLN showed robust type I immune responses and increased levels of CD8 and regulatory T cells in irradiated TDLN when compared with the control cohort. These immune responses were observed across all radiation dose groups, with the most pronounced effects in high dose TDLN. Significant changes in extracellular matrix and macrophage-associated gene signatures, indicating elevated fibrosis and prolonged inflammation, were observed in the TDLN with high radiation exposure, changes which were partially alleviated by immunotherapy.
conclusionIn the INCREASE trial, neoadjuvant IPI/NIVO combined with CRT for patients with T3-4N0-2 NSCLC elicited enhanced immune responses in TDLN despite exposure to high dose radiation. Even though radiation-induced fibrosis was evident in high dose TDLN, the immune responses were not diminished when compared with low dose TDLN. These findings underscore the resilience of TDLN immunological function under intense radiation exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.